Literature DB >> 26671045

Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.

Dasiuke Izumi1, Naoya Yoshida1, Masayuki Watanabe2, Shinya Shiraishi3, Takatsugu Ishimoto1, Keisuke Kosumi1, Ryuma Tokunaga1, Katsunobu Taki1, Takaaki Higashi1, Kazuto Harada1, Tatsunori Miyata1, Satoshi Ida2, Yu Imamura2, Shiro Iwagami1, Yoshifumi Baba1, Yasuo Sakamoto1, Yuji Miyamoto1, Yasuyuki Yamashita3, Hideo Baba4.   

Abstract

BACKGROUND: Positron emission tomography (PET) response criteria in solid tumors were recently proposed as a standardized method for the metabolic and quantitative assessment of response to chemotherapy. However, use of these criteria is limited in many institutions because of the need for exclusive software. This study was designed to clarify whether tumor to normal esophageal (T/N) ratio on (18)F-fluorodeoxyglucose PET/computed tomography could predict response to neoadjuvant chemotherapy and stratify prognosis in patients with esophageal squamous cell carcinoma (ESCC).
METHODS: Clinicopathological data were collected for 73 patients with ESCC who received neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by curative resection. The right liver lobe and normal esophagus were utilized as reference tissues for diagnosing complete metabolic response (CMR). Statistical methods included Kaplan-Meier analysis and univariate and multivariate Cox proportional hazards regression analyses.
RESULTS: CMR was achieved in 24 patients on the basis of maximum standardized uptake value (SUVmax) and in 11 on the basis of SUVmax evaluation with T/N ratio. Although prognosis was poorer in patients who achieved CMR than partial metabolic response based on SUVmax, the responses were significantly correlated with disease-free survival (DFS) based on SUVmax evaluation with T/N ratio (P = 0.0011). Receiver operating characteristic curve analysis showed that SUVmax evaluation with T/N ratio was the best predictor of pGrade 3. Multivariate analysis showed that SUVmax evaluation with T/N ratio was an independent predictor of DFS in patients with pGrade 1 pathologic response.
CONCLUSIONS: SUVmax evaluation with T/N ratio is useful for evaluating the effects of neoadjuvant chemotherapy in patients with ESCC.

Entities:  

Keywords:  DCF; ESCC; Neoadjuvant chemotherapy; SUVmax

Mesh:

Substances:

Year:  2015        PMID: 26671045     DOI: 10.1007/s00535-015-1150-4

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  19 in total

1.  Limited value of fluorine-18-fluorodeoxyglucose PET for the differential diagnosis of focal liver lesions in patients with chronic hepatitis C virus infection.

Authors:  O Schröder; J Trojan; S Zeuzem; R P Baum
Journal:  Nuklearmedizin       Date:  1998       Impact factor: 1.379

Review 2.  Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for patients with node-positive esophageal cancer.

Authors:  Masayuki Watanabe; Yohei Nagai; Kuichi Kinoshita; Seiya Saito; Junji Kurashige; Ryuichi Karashima; Kotaro Hirashima; Nobutaka Sato; Yu Imamura; Yukiharu Hiyoshi; Yoshifumi Baba; Shiro Iwagami; Yuji Miyamoto; Masaaki Iwatsuki; Naoko Hayashi; Hideo Baba
Journal:  Digestion       Date:  2011-01-21       Impact factor: 3.216

Review 3.  Targeted-therapy and imaging response: a new paradigm for clinical evaluation?

Authors:  Amalia Milano; Francesco Perri; Andrea Ciarmiello; Francesco Caponigro
Journal:  Rev Recent Clin Trials       Date:  2011-09

4.  Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.

Authors:  Laurent Bedenne; Pierre Michel; Olivier Bouché; Chantal Milan; Christophe Mariette; Thierry Conroy; Denis Pezet; Bernard Roullet; Jean-François Seitz; Jean-Philippe Herr; Bernard Paillot; Patrick Arveux; Franck Bonnetain; Christine Binquet
Journal:  J Clin Oncol       Date:  2007-04-01       Impact factor: 44.544

5.  CD44s regulates the TGF-β-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma.

Authors:  Kosuke Mima; Hirohisa Okabe; Takatsugu Ishimoto; Hiromitsu Hayashi; Shigeki Nakagawa; Hideyuki Kuroki; Masayuki Watanabe; Toru Beppu; Mayumi Tamada; Osamu Nagano; Hideyuki Saya; Hideo Baba
Journal:  Cancer Res       Date:  2012-05-02       Impact factor: 12.701

6.  A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).

Authors:  Nobutoshi Ando; Hoichi Kato; Hiroyasu Igaki; Masayuki Shinoda; Soji Ozawa; Hideaki Shimizu; Tsutomu Nakamura; Hiroshi Yabusaki; Norio Aoyama; Akira Kurita; Kenichiro Ikeda; Tatsuo Kanda; Toshimasa Tsujinaka; Kenichi Nakamura; Haruhiko Fukuda
Journal:  Ann Surg Oncol       Date:  2011-08-31       Impact factor: 5.344

7.  Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.

Authors:  Bryan H Burmeister; B Mark Smithers; Val Gebski; Lara Fitzgerald; R John Simes; Peter Devitt; Stephen Ackland; David C Gotley; David Joseph; Jeremy Millar; John North; Euan T Walpole; James W Denham
Journal:  Lancet Oncol       Date:  2005-09       Impact factor: 41.316

Review 8.  From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Authors:  Richard L Wahl; Heather Jacene; Yvette Kasamon; Martin A Lodge
Journal:  J Nucl Med       Date:  2009-05       Impact factor: 10.057

9.  Influence of preoperative docetaxel, cisplatin, and 5-fluorouracil on the incidence of complications after esophagectomy for resectable advanced esophageal cancer.

Authors:  N Yoshida; M Watanabe; Y Baba; T Ishimoto; S Iwagami; Y Sakamoto; Y Miyamoto; R Karashima; H Baba
Journal:  Dis Esophagus       Date:  2013-08-09       Impact factor: 3.429

10.  PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.

Authors:  Florian Lordick; Katja Ott; Bernd-Joachim Krause; Wolfgang A Weber; Karen Becker; Hubert J Stein; Sylvie Lorenzen; Tibor Schuster; Hinrich Wieder; Ken Herrmann; Rainer Bredenkamp; Heinz Höfler; Ulrich Fink; Christian Peschel; Markus Schwaiger; Jörg R Siewert
Journal:  Lancet Oncol       Date:  2007-09       Impact factor: 41.316

View more
  6 in total

1.  Intratumoral Fusobacterium Nucleatum Levels Predict Therapeutic Response to Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma.

Authors:  Kensuke Yamamura; Daisuke Izumi; Raju Kandimalla; Fuminori Sonohara; Yoshifumi Baba; Naoya Yoshida; Yasuhiro Kodera; Hideo Baba; Ajay Goel
Journal:  Clin Cancer Res       Date:  2019-07-29       Impact factor: 12.531

Review 2.  Esophageal cancer: The latest on chemoprevention and state of the art therapies.

Authors:  Gregoire F Le Bras; Muhammad H Farooq; Gary W Falk; Claudia D Andl
Journal:  Pharmacol Res       Date:  2016-08-24       Impact factor: 7.658

3.  Association of the primary tumor's SUVmax with survival after surgery for clinical stage IA esophageal cancer: a single-center retrospective study.

Authors:  Yutaka Miyawaki; Hiroshi Sato; Naoto Fujiwara; Shuichiro Oya; Hirofumi Sugita; Yasumitsu Hirano; Tomohiko Yamane; Shinichi Sakuramoto; Kojun Okamoto; Shigeki Yamaguchi; Isamu Koyama
Journal:  Int J Clin Oncol       Date:  2019-12-23       Impact factor: 3.402

4.  Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma.

Authors:  Yang Liu; Yoshifumi Baba; Takatsugu Ishimoto; Hiroyasu Tsutsuki; Tianli Zhang; Daichi Nomoto; Kazuo Okadome; Kensuke Yamamura; Kazuto Harada; Kojiro Eto; Yukiharu Hiyoshi; Masaaki Iwatsuki; Yohei Nagai; Shiro Iwagami; Yuji Miyamoto; Naoya Yoshida; Yoshihiro Komohara; Masaki Ohmuraya; Xiaoming Wang; Jaffer A Ajani; Tomohiro Sawa; Hideo Baba
Journal:  Br J Cancer       Date:  2020-12-10       Impact factor: 7.640

5.  A Novel Theranostic Combination of Near-infrared Fluorescence Imaging and Laser Irradiation Targeting c-KIT for Gastrointestinal Stromal Tumors.

Authors:  Shota Fujimoto; Naoki Muguruma; Koichi Okamoto; Takeshi Kurihara; Yasushi Sato; Yoshihiko Miyamoto; Shinji Kitamura; Hiroshi Miyamoto; Takahiro Taguchi; Koichi Tsuneyama; Tetsuji Takayama
Journal:  Theranostics       Date:  2018-03-21       Impact factor: 11.556

6.  18F-fluorodeoxyglucose positron emission tomography predicts lymph node responses to definitive chemoradiotherapy in esophageal squamous cell carcinoma patients.

Authors:  Wenyao Zhu; Yan Zhang; Li Kong; Yong Huang; Jinsong Zheng; Renben Wang; Minghuan Li; Jinming Yu
Journal:  Onco Targets Ther       Date:  2018-07-25       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.